A Study to Evaluate EDP 938 Regimens in Children With RSV

NCT ID: NCT04816721

Last Updated: 2025-07-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-26

Study Completion Date

2024-08-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, dose ranging, placebo-controlled study in respiratory syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to 36 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and antiviral activity of a 5 day treatment with EDP-938.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus (RSV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EDP-938

EDP-938, oral suspension, once daily for 5 days

Group Type EXPERIMENTAL

EDP-938

Intervention Type DRUG

Oral suspension

Placebo

Matching placebo, orally, once daily for 5 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo oral suspension to match EDP-938

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EDP-938

Oral suspension

Intervention Type DRUG

Placebo

Placebo oral suspension to match EDP-938

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female who is either ≥6 months to ≤36 months (for Age Group 1) or ≥28 days to \<6 months (for Age Group 2), defined at the time of randomization. Subjects in Age Group 2 must have been born ≥29 weeks of gestation to be eligible.
* Subjects diagnosed with RSV infection
* Subjects with signs of an acute respiratory illness with onset ≤7 days for Part 1 and ≤5 days for Part 2 before the time of signing the ICF
* In the Investigator's opinion, the subject's caregiver understands and is able to comply with protocol requirements, instructions, and protocol-stated restrictions, and the subject is likely to complete the study as planned

Exclusion Criteria

* Use of or anticipated need for invasive mechanical ventilation, cardiopulmonary bypass, hemodialysis, or extracorporeal membrane oxygenation; or subjects who are not expected to survive the current illness
* Underlying immune deficiency, (e.g., from confirmed human immunodeficiency virus infection or use of an immunosuppressive medication except immunoglobulin A deficiency)
* Receipt of (within 12 months before Screening) or on a waiting list for a bone marrow, stem cell, or solid organ transplant, or who received radiation or chemotherapy (within 12 months before screening)
* Receiving chronic oxygen therapy at home before admission
* Subjects whose mother received an investigational RSV vaccination while pregnant with the subject if they were born at term (≥37 weeks of gestation) and are less than 12 months of age
* In Part 2, subjects dosed with an investigational or approved medication that is intended to prevent or treat RSV infection within the following times before the first dose of study drug: ribavirin 35 days; palivizumab 100 days; nirsevimab 350 days; other RSV-specific monoclonal antibody 5 half-lives of the specific antibody; RSV vaccines 12 months.
Minimum Eligible Age

28 Days

Maximum Eligible Age

36 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Enanta Pharmaceuticals, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Enanta Pharmaceuticals, Inc

Role: STUDY_DIRECTOR

Enanta Pharmaceuticals, Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Care Miller Children's and Women's Hospital

Long Beach, California, United States

Site Status

University of California Los Angeles (UCLA)

Los Angeles, California, United States

Site Status

University of California Davis

Sacramento, California, United States

Site Status

Nemours Children's Hospital

Orlando, Florida, United States

Site Status

South Tampa Center for Advanced Healthcare

Tampa, Florida, United States

Site Status

Rexburg Pediatrics

Rexburg, Idaho, United States

Site Status

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

Norton Children's Research Institute

Louisville, Kentucky, United States

Site Status

MedPharmics - Lafayette

Lafayette, Louisiana, United States

Site Status

LSU Health

Shreveport, Louisiana, United States

Site Status

Willis-Knighton Health System

Shreveport, Louisiana, United States

Site Status

Boston Children's Hospital - Division of Adolescent/Youth Adult Medicine

Boston, Massachusetts, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Site Status

Driscoll Children's Hospital

Corpus Christi, Texas, United States

Site Status

Children's Health Specialty Center Dallas Campus

Dallas, Texas, United States

Site Status

Clinica del Niño y la Familia

Mar del Plata, Buenos Aires, Argentina

Site Status

Hospital Interzonal Dr Jose Penna

Bahía Blanca, , Argentina

Site Status

Clínica Privada del Sol

Buenos Aires, , Argentina

Site Status

Instituto Medico Rio Cuarto

Río Cuarto, , Argentina

Site Status

Clinica Central S.A

Villa Regina, , Argentina

Site Status

Sydney Children's Hospital - Randwick

Randwick, New South Wales, Australia

Site Status

The Children's Hospital at Westmead

Westmead, New South Wales, Australia

Site Status

Gold Coast University Hospital

Southport, , Australia

Site Status

Instituto Méderi de Pesquisa e Saúde

Passo Fundo, Rio Grande do Sul, Brazil

Site Status

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Irmandade da Santa Casa de Misericórdia Hospital - Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Universidade Federal do Paraná - Hospital de Clínicas

Curitiba, , Brazil

Site Status

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto

Ribeirão Preto, , Brazil

Site Status

Universitätsklinikum Gießen und Marburg - Gießen

Marburg, Bundesland, Germany

Site Status

Universitätsklinikum Erlangen

Erlangen, , Germany

Site Status

Asklepios Klinik Sankt Augustin

Sankt Augustin, , Germany

Site Status

Soroka University Medical Center

Beersheba, , Israel

Site Status

Rambam Health Care

Haifa, , Israel

Site Status

Carmel Medical Center

Haifa, , Israel

Site Status

Hadassah University Hospital Mount Scopu

Jerusalem, , Israel

Site Status

Schneider Children's Medical Center Of Israel

Petah Tikva, , Israel

Site Status

Panamerican Clinical Research Mexico - Guadalajara

Guadalajara, Prados, Mexico

Site Status

Instituto Nacional de Pediatría

Mexico City, , Mexico

Site Status

Hospital Infantil De Mexico Federico Gomez

Mexico City, , Mexico

Site Status

Karla Adriana Espinosa Bautista

Mexico City, , Mexico

Site Status

IESCI Clinical Research

Monterrey, , Mexico

Site Status

PanAmerican Clinical Research

Querétaro, , Mexico

Site Status

SMIQ S de R.L de C.V

Querétaro, , Mexico

Site Status

Wellington Regional Hospital

Newtown, Wellington Region, New Zealand

Site Status

IN-VIVO Bydgoszcz

Bydgoszcz, , Poland

Site Status

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi

Lodz, , Poland

Site Status

Spital Clinic de Urgenta Pentru Copii Brasov

Brasov, Brașov County, Romania

Site Status

Spitalul Clinic Judetean De Urgenta Târgu Mureș

Târgu Mureş, Târgu Mureș, Romania

Site Status

Institutul National pentru Sanatatea Mamei si Copilului "Alessandrescu-Rusescu"

Bucharest, , Romania

Site Status

Life Westville Hospital

Westville, Durban, South Africa

Site Status

Rahima Moosa Mother and Child Hospital

Johannesburg, , South Africa

Site Status

Wits Clinical Research

Soweto, , South Africa

Site Status

Nowon Eulji Medical Center, Eulji University

Seoul, , South Korea

Site Status

Kyung Hee University Hospital

Seoul, , South Korea

Site Status

Inje University Sanggye Paik Hospital

Seoul, , South Korea

Site Status

Hospital Germans Trias i Pujol

Barcelona, , Spain

Site Status

Hospital Universitario Arnau de Vilanova

Lleida, , Spain

Site Status

Hospital Clínico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Hospital Universitario Fundación Jiménez Díaz

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Universitario Puerta de Hierro - Majadahonda

Madrid, , Spain

Site Status

Hospital Universitario Quirónsalud Madrid

Madrid, , Spain

Site Status

Hospital Universitario Severo Ochoa

Madrid, , Spain

Site Status

Unidad de Ensayos Clínicos Pediátricos

Madrid, , Spain

Site Status

Hospital Regional Universitario de Málaga

Málaga, , Spain

Site Status

Hospital Clínico Universitario de Santiago

Santiago de Compostela, , Spain

Site Status

Hospital Universitario Joan XXIII de Tarragona

Tarragona, , Spain

Site Status

National Taiwan University Hospital

Taipei City, Taipei, Taiwan

Site Status

Linkou Chang Gung Memorial Hospital, Chang Gung Medical Foundation

Taoyuan, Taoyuan, Taiwan

Site Status

Hsinchu Mackay Memorial Hospital

Hsinchu, , Taiwan

Site Status

Chang Gung Memorial Hospital - Kaohsiung Branch

Kaohsiung City, , Taiwan

Site Status

Chung Shan Medical University Hospital

Taichung, , Taiwan

Site Status

Taipei Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

Nottingham University Hospitals NHS Trust

Nottingham, Nottinghamshire, United Kingdom

Site Status

St. George's University Hospitals NHS Foundation Trust

London, , United Kingdom

Site Status

Sheffield Children's NHS Foundation Trust

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Germany Israel Mexico New Zealand Poland Romania South Africa South Korea Spain Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EDP 938-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.